Thyroid/H&N Cancers
FDA Approves Neoadjuvant and Adjuvant Keytruda for Resectable, Locally Advanced Head and Neck SCC
This is the first approval for HNSCC in six years and the first overall perioperative approval for locally advanced HNSCC.
JUNE 13, 2025
FDA Approves Penpulimab for Non-Keratinizing Nasopharyngeal Carcinoma
The FDA has approved penpulimab-kcqx (Akeso Biopharma) with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.
APRIL 25, 2025
FDA Fully Approves Retevmo for RET Fusion-Positive Medullary Thyroid Cancer
The FDA has granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.
SEPTEMBER 30, 2024
FDA Grants Traditional Approval to Retevmo for RET Fusion–Positive Thyroid Cancer
The FDA has granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients aged 2 years and older with advanced or metastatic RET fusion–positive thyroid cancer who require systemic therapy and who are radioactive iodine (RAI)-refractory, if RAI is appropriate.
JUNE 14, 2024
Retevmo Approved for Pediatric Patients with RET-altered Metastatic Thyroid Cancer or Solid Tumors
The FDA has granted accelerated approval to selpercatinib (Retevmo, Lilly.
MAY 30, 2024
Sarcopenia Before Neoadjuvant Chemo Predicts Mortality in EGA Patients
Sarcopenia before neoadjuvant treatment of esophagogastric adenocarcinoma is associated with significantly higher mortality rates in the five years after surgery.
JANUARY 19, 2024
FDA Approves Loqtorz for Nasopharyngeal Carcinoma
The FDA approved toripalimab-tpzi (Loqtorz, Coherus BioSciences) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma. The FDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic nasopharyngeal carcinoma with disease progression on or after a platinum-containing chemotherapy.
OCTOBER 30, 2023
Head and Neck Cancer Care Comes at High Cost
Patients with head and neck cancer have elevated treatment expenses for at least five years after diagnosis, according to a recently published study aimed at quantifying healthcare costs following this diagnosis.
JANUARY 13, 2023
Checkpoint Inhibitor Plus CRT Misses End Point in Advanced Head and Neck Cancer
In patients with locally advanced head and neck squamous cell carcinoma (HNSCC), the combination of the checkpoint inhibitor pembrolizumab (Keytruda, Merck) plus chemoradiation therapy (CRT) fell short of the primary end point of event-free survival (EFS) in a phase 3 multicenter trial.
NOVEMBER 2, 2022
Cabozantinib Beneficial in Radioactive Iodine-Refractory DTC
Cabozantinib significantly improved progression-free survival in certain patients with radioactive iodine-refractory differentiated thyroid cancer, according to results from the COSMIC-311 study.
NOVEMBER 3, 2021
Cabometyx Approved for Metastatic Differentiated Thyroid Cancer
The FDA approved cabozantinib (Cabometyx, Exelixis) for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed after vascular endothelial growth factor (VEGFR)-targeted therapy and who are ineligible or refractory to radioactive iodine.
SEPTEMBER 30, 2021
Gavreto Approved for Treatment of RET-Altered Thyroid Cancers
The FDA approved pralsetinib (Gavreto, Genentech/Blueprint Medicines) for patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy or RET fusion–positive thyroid cancer who require systemic therapy and are radioactive iodine–refractory, if radioactive iodine is appropriate.
DECEMBER 3, 2020
